论文部分内容阅读
全球激素避孕药巨头德国先灵集团日前在京举行了盛大的在华业务120周年庆典。在庆典上,德国先灵公司执行董事会主席Erlen博士宣布:除了影像诊断、抗肿瘤领域外,先灵公司将花更大力气投入中国口服避孕药市场,未来7年计划引进多种独具特色的避孕药,给中国妇女更多样化的选择。据悉,继去年12月在华上市三相口服避孕药“特居乐”之后,先灵另一款避孕新药“优思明”中国上市前的临床试验和注册也在紧张进行中。
Global hormonal contraceptive giant Germany Schering AG recently held a grand celebration of the 120th anniversary of its business in China. At the ceremony, Dr. Erlen, Chairman of the Executive Board of Schering AG announced that Schering AG will devote more effort to the Chinese oral contraceptive market besides imaging diagnosis and anti-tumor. In the next 7 years, it plans to introduce a number of unique Birth control pills, giving Chinese women a more diverse choice. It is reported that following the listing of China in December last year, three-phase oral contraceptives “live in music”, the other contraceptives before the spleen, “Yasmin” China’s pre-market clinical trials and registration is also underway.